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Abstract
Background: The role of asymptomatic carriers of toxigenic Clostridium difficile (TCD) in nosocomial
cross-transmission remains debatable. Moreover, its relevance in the elderly has been sparsely studied.
Objectives: To assess asymptomatic TCD carriage in an acute care geriatric population.
Methods: We performed a prospective cohort study at the 296-bed geriatric hospital of the Geneva University
Hospitals. We consecutively recruited all patients admitted to two 15-bed acute-care wards. Patients with C. difficile
infection (CDI) or diarrhoea at admission were excluded. First bowel movement after admission and every two
weeks thereafter were sampled. C. difficile toxin B gene was identified using real-time polymerase chain-reaction
(BD MAXTMCdiff). Asymptomatic TCD carriage was defined by the presence of the C. difficile toxin B gene without
diarrhoea.
Results: A total of 102 patients were admitted between March and June 2015. Two patients were
excluded. Among the 100 patients included in the study, 63 were hospitalized and 1 had CDI in the
previous year, and 36 were exposed to systemic antibiotics within 90 days prior to admission. Overall,
199 stool samples were collected (median 2 per patient, IQR 1-3). Asymptomatic TCD carriage was
identified in two patients (2 %).
Conclusions: We found a low prevalence of asymptomatic TCD carriage in a geriatric population frequently
exposed to antibiotics and healthcare. Our findings suggest that asymptomatic TCD carriage might contribute
only marginally to nosocomial TCD cross-transmission in our and similar healthcare settings.
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Introduction
Clostridium difficile infection (CDI) is currently the
most commonly reported pathogen causing healthcare-
associated infections in the United States [1]. Moreover,
it is associated with significant morbidity and mortality,
particularly among older people [1].
There is ongoing controversy about the role of asymp-
tomatic carriage in the transmission of toxigenic C. difficile
(TCD) in healthcare facilities [2]. Indeed, asymptomatic
TCD carriers have been implicated in TCD cross-
transmission in hospitals [3]. Importantly, as they are not a
focus of CDI control measures, asymptomatic TCD carriers
may constitute an important reservoir for nosocomial
transmission [3].
Data on asymptomatic TCD carriage in elderly hospi-
talized patients remains scarce. In this context, we aimed
to assess the prevalence of asymptomatic TCD carriage
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at admission to an acute care geriatric hospital and the
rate of nosocomial acquisition during inpatient stay.
Methods
The study was performed in the geriatric hospital of the
Geneva University Hospitals. In this 296-bed hospital,
the incidence of CDI from 1st January until 31st July
2015 was 1.97/10 000 patient-days (without any major
clustering). The overall antibiotic use density in 2014
was 220 Defined Daily Doses/1000 patient-days.
All patients consecutively admitted to two 15-bed
acute care wards were eligible for inclusion. Patients
were recruited from 2nd March until 30th June 2015. Pa-
tients with diagnosis of CDI and/or diarrhoea (defined
as ≥3 unformed stools/day) during the first 48 h after
hospitalization were excluded.
We collected the first bowel movement after admis-
sion, and every two weeks thereafter (or earlier, if dis-
charge occurred ≤2 weeks after admission). Patients
were followed until discharge. Immediately after a pa-
tient’s bowel movement, the stool sample was placed on
Cary-Blair® medium for transport to the laboratory. The
C. difficile toxin B gene was identified using real-time
polymerase chain reaction (PCR) (BD MAXTM Cdiff, BD
diagnostics, Sparks, Maryland).
Asymptomatic TCD carriage was defined as presence
of C. difficile toxin B gene without symptoms of diar-
rhoea at the time of stool collection. If identified in the
first 72 h of hospitalization, the case was classified as
asymptomatic carrier at admission. If identified after
72 h and with a previous negative result, it was consid-
ered as nosocomial acquisition. If the patient was identi-
fied after 72 h of hospitalization but without a previous
negative sample, we considered it as non-classifiable re-
garding place of TCD acquisition.
We retrieved information about CDI and hospitalization
in the previous year, medications prescribed within 90 days
before admission, origin of patient (home, long-term care
facility or hospital transfer), demographics, comorbidities,
administration of systemic antibiotics during hospitalization
and length of stay. Data was manually collected from elec-
tronic charts.
CDI patients were placed under contact precautions in
single rooms and asymptomatic TCD carriers were sub-
mitted to standard precautions. The staff was unaware
of a patient’s TCD status. Ethical approval was obtained
without the need for individual consent.
Results
During the study period, 102 patients were admitted to
the two acute-care wards. Two patients were excluded
from the study at admission (one had CDI and one had
diarrhoea). Among the 100 included patients, 63 had
been hospitalized and one had had a CDI diagnosis in
the previous 12 months. Thirty-six had been exposed to
systemic antibiotics, 3 to corticotherapy and 41 to pro-
ton pump inhibitors within 90 days before admission.
Finally, 7 had been admitted from long-term care facil-
ities (LTCF; Table 1).
A total of 199 stool samples were collected from 95
patients. Twenty-eight patients had only one sample col-
lected, 39 had 2 and 28 had ≥3. We couldn’t obtain sam-
ples from five patients because of lack of collaboration
on stool collection.
The median number of samples collected per patient
was 2 [interquartile range (IQR) 1–3]. The first sample
was collected at a median of 3 days (IQR, 1–4) and the
second sample at a median of 14 days (IQR, 10–17) after
admission. Fifty-nine patients had stool samples collected
in the first 72 h of hospitalization. For patients for whom
two or more samples (67) were collected, the last collec-
tion was performed at a median of 6 days (IQR, 2–12)
before discharge.
Asymptomatic TCD carriage was identified in two pa-
tients. Patient 1 had positive samples at admission (day 1)
and at the date of discharge (day 29). Patient 2 had a first
test on day 4 that was non-interpretable (due to non-
amplification of the internal control of C. difficile BD
MAX®; this test was not repeated due to lack of remaining
sample material) and a second test that was positive on
day 17. According to the study definitions, patient 1 was
considered asymptomatic TCD carrier at admission and
patient 2 was non-classifiable regarding place of TCD ac-
quisition. Both of these patients received antibiotic treat-
ment during hospital stay, and remained asymptomatic.
Patient 1 was treated with amoxicillin/clavulanate (2 days)
and piperacillin/tazobactam (7 days) for complicated
community-acquired pneumonia and patient 2 received
ceftriaxone (3 days) and ciprofloxacin (4 days) for
community-acquired urinary tract infection. No case of
symptomatic CDI was diagnosed within the 2 wards dur-
ing the study period.
Discussion
We found a very low frequency of asymptomatic car-
riage of TCD (2 %) at an acute care geriatric hospital in
Switzerland.
This is one of the few studies to address TCD asymp-
tomatic carriage in geriatric population and the first to
be conducted in Switzerland. These results provide valu-
able epidemiological insight into the understanding of
CDI, a frequent and severe condition in the geriatric
population.
Importantly, our data stand in contrast with similar
studies, conducted in heterogeneous acute care hospital
populations, that found higher frequencies of asymptom-
atic TCD carriage. Indeed, frequencies ranging from 4 to
50 % were reported in studies of variable duration (from
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2 months up to 1.5 years) and in different settings [2–5].
Our findings are even more striking if we take into ac-
count that studies in LTCF and other chronic-care geriat-
ric facilities have also reported higher rates of TCD
carriage (up to 51 % during an outbreak in a LTCF) [5, 6].
To explain our results, one might argue that some var-
iables typically associated with asymptomatic TCD car-
riage, such as history of CDI, corticotherapy or residency
in LTCF [4, 5], were not frequent in our population.
However, our cohort was mainly constituted by patients
with a previous hospitalization and exposed to proton
pump inhibitors, and those factors are also frequently
linked with TCD carriage [4, 5]. Our patients also had a
high rate of antibiotic exposure, both prior to and during
hospitalization. However, this variable is considered to
be more associated with CDI than with asymptomatic
carriage [4, 5].
Our findings and the variable rates of TCD carriage
reported in studies from acute care hospitals and LTCF,
suggest that factors determining asymptomatic carriage
may be multiple, not easily identifiable and still incom-
pletely understood [7].
Recent literature argued for an important contribution of
asymptomatic carriers in nosocomial cross-transmission of
TCD [3]. On the contrary, our study findings suggest that,
in our setting, asymptomatic TCD carriers do not appear to
contribute to cross-transmission of TCD. One may
hypothesize that, in addition to patient-related risk factors,
several healthcare-related aspects may also influence the
relative contribution of asymptomatic TCD carriage to the
epidemiology of CDI. Those aspects may include the over-
all CDI incidence (including the occurrence of outbreaks),
the pattern of antibiotic utilization and infection prevention
practices.
We found four other studies investigating asymptomatic
TCD carriage in acute care geriatric hospitals, and only
one of them was published in the last 10 years [8–11].
Interestingly, all those studies have found a low prevalence
of asymptomatic carriage at admission (0-2 %). Two of
them also evaluated the incidence of in-hospital acquisi-
tion of asymptomatic TCD carriage, which ranged from 0
to 12 % [8, 10]. The most recent study, performed in 2011
by Schoevaerdts et al. during a 1-year period in a 26-bed
geriatric hospital, reported a frequency of asymptomatic
TCD carriage at admission even lower than ours (2/336),
and no cases of in-hospital acquisition of asymptomatic
TCD carriage [8]. This study may be criticized since it
only included 336 out of 473 (71 %) potentially eligible pa-
tients, which could possibly have lead to selection bias [8].
In our study, we included all eligible patients and man-
aged to obtain a very high compliance rate of stool
collection (95 %).
Table 1 Characteristics of the 100 included patients in the prospective cohort study
Variable No stool samples n = 5 No TCD colonization n = 93 TCD asymptomatic carriers n = 2*
Male sex 2 21 (23) 1
Age, median years (IQR) 82 (81–83) 85 (80–90) 82/81
Charlson comorbidity index, median (IQR) 8 (5–9) 6 (5–8) 4/6
Medication in the 90 days prior to admission:
Antibiotic therapy 1 33 (35) 2
Proton pump inhibitors 3 38 (41) 0
Corticotherapy (>25 mg/day) 0 2 (2) 1
Diagnosis of CDI in previous year 0 1 (1) 0
Hospital stay in previous year 4 57 (61) 2
Hospital stay in previous 90 days 3 41 (44) 2
Length of last hospital stay, median days (IQR) 27 (15–37) 16 (5–25) 124/5
Origin at ward admission:
Home 4 76 (82) 1
LTCF 1 6 (6) 0
Transferred from another ward 0 11 (12) 1
Length of current ward stay in days, median (IQR) 10 (9–14) 24 (14–37) 30/29
Antibiotic therapy during ward stay 2 36 (39) 2
Values are n (%) or as indicated
*Because these data concern only two patients, we decided to specify the values for continuous or categorical variables and to not state p values
CDI Clostridium difficile infection
IQR inter quartile range
LTCF long-term care facilities
TCD toxigenic Clostridium difficile
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Our study has several limitations. First of all, there is
no established gold-standard method for the diagnosis of
asymptomatic TCD carriage. In our study, we used PCR
to identify asymptomatic TCD carriers. Although PCR
assays have high sensitivity and specificity and are widely
used to diagnose CDI [12], their use to identify asymp-
tomatic TCD carriers has not been established on a de-
finitive base. Concerns may be raised regarding the
analytical sensitivity of PCR, because C. difficile counts
in asymptomatic TCD carriers are lower than in CDI [6].
Donskey et al. [13] only identified 68 % of asymptomatic
TCD carriers with a commercial PCR assay. The analysis
of perirectal swabs of doubtful diagnostic quality and the
higher limit of detection of that assay as compared with
alternative PCR assays [14–16], may have contributed to
that result. Conversely, several large studies used PCR
for the diagnosis of asymptomatic TCD carriage and
obtained comparable results to studies using toxigenic
culture (which is still considered the gold standard for
the diagnosis of CDI) [17, 18]. In particular, Hung et al
[18] detected more asymptomatic TCD carriers with a
PCR assay than with toxigenic culture.
Other limitations worth mentioning are the small sam-
ple size of our study and its single center setting. Add-
itionally, it is known that CDI occurrence follows a
seasonal pattern, with peaks in winter and early spring
[19]. Supposed that TCD carriage follows the same sea-
sonal pattern, the fact that our study was performed
from March to June could have slightly underestimated
the true carriage rates. Finally, suboptimal compliance
with follow-up sampling makes firm conclusions about
nosocomial TCD acquisition difficult to establish.
Conclusions
We found a low prevalence of asymptomatic TCD carriage
in geriatric patients, frequently exposed to antibiotics and
to the healthcare system. This adds to the ongoing contro-
versy regarding the prevalence and role of asymptomatic
TCD colonization in nosocomial cross-transmission. More
studies are needed to address C. difficile epidemiology in
the geriatric population.
Abbreviations
CDI, Clostridium difficile infection; DDD, defined daily doses; IQR, interquartile
range; LTCF, long-term care facilities; PCR, polymerase chain reaction; TCD,
toxigenic C. difficile
Acknowledgments
The authors acknowledge the medical and nursing team in the geriatric
hospital, especially the chief nurse Marc Desilets, as well as Iker Uckay and
Américo Agostinho. We would also like to thank José Melo Cristino from the
Instituto de Microbiologia, Faculdade de Medicina, Universidade de Lisboa
for the support and Yves Longtin from the Jewish General Hospital and
McGill University, Montreal, Canada for the advice provided.
Funding
The kits for C. difficile toxin B gene identification on BD MAXTM Cdiff were
kindly provided by BD®, without charges. BD® was not involved by any
means in the design of the study and collection, analysis, and interpretation
of data and in writing the manuscript. Internal funding was used for
microbiologic analyses.
DP was partially supported by Fundação para a Ciência e Tecnologia (SFRH/
SINT/95317/2013). CF and BH were supported by the European Commission
under the Life Science Health Priority of the 7th Framework Program (R-
GNOSIS grant agreement 282512).
Availability of data and materials
All the data supporting conclusions are available in Table 1.
Authors’ contributions
DP, VP, CF and VS coordinated and performed the data collection. JS and GR
coordinated and carried out the microbiological analysis. DP, BH and SH
conceived the study, participated in its design and drafted the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Ethical approval was obtained from the Research Ethics Commission of
Geneva without the need for individual consent (reference number: CEREH
13-187).
Author details
1Infection Control Program, Geneva University Hospitals, 4, rue Gabrielle
Perret-Gentil, 1211 Geneva, Switzerland. 2Department of Infectious Diseases,
Centro Hospitalar Lisboa Norte and Faculdade de Medicina da Universidade
de Lisboa, Lisbon, Portugal. 3Department of Geriatrics, Geneva University
Hospitals, Geneva, Switzerland. 4Central Laboratory of Bacteriology, Geneva
University Hospitals, Geneva, Switzerland. 5Department of Infectious Diseases,
Geneva University Hospitals, Geneva, Switzerland. 6Faculty of Medicine,
University of Geneva, Geneva, Switzerland.
Received: 29 February 2016 Accepted: 1 June 2016
References
1. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey
of health care-associated infections. N Engl J Med. 2014;370(13):1198–208.
doi:10.1056/NEJMoa1306801.
2. Donskey CJ, Kundrapu S, Deshpande A. Colonization versus carriage of
Clostridium difficile. Infect Dis Clin North Am. 2015;29(1):13–28. doi:10.1016/
j.idc.2014.11.001.
3. Curry SR, Muto CA, Schlackman JL, et al. Use of multilocus variable number
of tandem repeats analysis genotyping to determine the role of
asymptomatic carriers in Clostridium difficile transmission. Clin Infect Dis.
2013;57(8):1094–102. doi:10.1093/cid/cit475.
4. Kong LY, Dendukuri N, Schiller I, et al. Predictors of asymptomatic
Clostridium difficile colonization on hospital admission. Am J Infect Control.
2015;43(3):248–53. doi:10.1016/j.ajic.2014.11.024.
5. Furuya-Kanamori L, Marquess J, Yakob L, et al. Asymptomatic Clostridium
difficile colonization: epidemiology and clinical implications. BMC Infect Dis.
2015;15:516. doi:10.1186/s12879-015-1258-4.
6. Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RLP, Donskey CJ.
Asymptomatic carriers are a potential source for transmission of epidemic
and nonepidemic Clostridium difficile strains among long-term care facility
residents. Clin Infect Dis. 2007;45(8):992–8. doi:10.1086/521854.
7. Harbarth S, Samore MH. Clostridium: transmission difficile? PLoS Med. 2012;
9(2):e1001171. doi:10.1371/journal.pmed.1001171.
8. Schoevaerdts D, Swine C, Verroken A, Huang T-D, Glupczynski Y.
Asymptomatic colonization by Clostridium difficile in older adults admitted
to a geriatric unit: a prospective cohort study. J Am Geriatr Soc. 2011;59(11):
2179–81. doi:10.1111/j.1532-5415.2011.03685.x.
9. McCoubrey J, Starr J, Martin H, Poxton IR. Clostridium difficile in a geriatric
unit: a prospective epidemiological study employing a novel S-layer typing
method. J Med Microbiol. 2003;52(Pt 7):573–8. doi:10.1099/jmm.0.05179-0.
Pires et al. Antimicrobial Resistance and Infection Control  (2016) 5:24 Page 4 of 5
10. Rudensky B, Rosner S, Sonnenblick M, Van Dijk Y, Shapira E, Isaacsohn M.
The prevalence and nosocomial acquisition of Clostridium difficile in elderly
hospitalized patients. Postgrad Med J. 1993;69(807):45–7.
11. Corrado OJ, Mascie-Taylor BH, Hall MJ, Bolton RP. Prevalence of Clostridium
difficile on a mixed-function ward for the elderly. J Infect. 1990;21:187–292.
12. Burnham C-AD, Carroll KC. Diagnosis of Clostridium difficile Infection: an
ongoing conundrum for clinicians and for clinical laboratories. Clin
Microbiol Rev. 2013;26(3):604–30. doi:10.1128/CMR.00016-13.
13. Donskey CJ, Sunkesula VCK, Jencson AL, et al. Utility of a commercial
PCR assay and a clinical prediction rule for detection of toxigenic
clostridium difficile in asymptomatic carriers. J Clin Microbiol. 2014;52(1):
315–8. doi:10.1128/JCM.01852-13.
14. BD GenOhmTM Cdif Assay. Package insert. BD diagnostics, San Diego,
CA. July 2008. https://www.bd.com/resource.aspx?IDX=17953 (accessed
February 2016)
15. BD MAXTM Cdiff Assay. Package insert. BD diagnostics, Sparks,
Maryland. April 2013. http://moleculardiagnostics.bd.com/product/max/
(accessed February 2016)
16. Xpert® C. difficile. Package insert. Cepheid, Sunnyvale, CA. May 2012. http://
www.diagnostictechnology.com.au/persistent/catalogue_files/products/
xpertcdifficilepi.pdf (accessed February 2016)
17. Tschudin-Sutter S, Carroll KC, Tamma PD, et al. Impact of toxigenic
clostridium difficile colonization on the risk of subsequent C. difficile
infection in intensive care unit patients. Infect Control Hosp Epidemiol.
2015;36(11):1324–9. doi:10.1017/ice.2015.177.
18. Hung Y-P, Tsai P-J, Hung K-H, et al. Impact of toxigenic Clostridium
difficile colonization and infection among hospitalized adults at a
District Hospital in Southern Taiwan. PLoS One. 2012;7(8):e42415. doi:10.
1371/journal.pone.0042415.
19. Furuya-Kanamori L, McKenzie SJ, Yakob L, et al. Clostridium difficile infection
seasonality: patterns across hemispheres and continents–A systematic
review. PLoS One. 2015;10(3):e0120730. doi:10.1371/journal.pone.0120730.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Pires et al. Antimicrobial Resistance and Infection Control  (2016) 5:24 Page 5 of 5
